Drugs / VNZ/TEZ/D-IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05844449 | Aug 2023 → Jul 2029 expected | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNZ/TEZ/D-IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844449 ↗ |
| Route | Oral | “Fixed-dose combination tablets or granules for oral administration.” NCT05844449 ↗ |